Global Healthcare Public Health

Obesity by Country

Last updated: August 24, 2011 11:19 am

PatrickDriscoll

1 Min Read

The global obesity market is steadily growing as a result of increased prevalence and recognition by governments and industry of the severity of the problem. However, the severity of the problem (and the associated opportunity to provide solutions) varies considerably from country to country.

The global obesity market is steadily growing as a result of increased prevalence and recognition by governments and industry of the severity of the problem. However, the severity of the problem (and the associated opportunity to provide solutions) varies considerably from country to country. While western democracies and their well developed consumer markets and standards of living allow consumption to excess, less well developed markets demonstrate considerably less utilization yet, in some cases (such as China), show considerably greater potential as their economies rapidly grow and become more “western-like”.

Below is illustrated, for select countries, the total clinical obesity treatment market per country in the aggregate and as a per capita value.

Source: MedMarket Diligence, LLC: Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”

TAGGED:global healthcare obesity public health

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.